Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 140

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 140
---
        
 the combined entity. Another $250,000 of shares of Common Stock will be issued at 90 and 180 days after the effectiveness of a registration 
 statement filed by CERo to register such shares.                                                                                            |

82 Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations The pro forma adjustments included in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023, are as follows:

| AA. | Reflects                                                                                                
 Legacy CERo’s and PBAX’s additional $3.8 million of transaction costs incurred after December 31, 2023. |

| BB. | Reflects                                                                                                                                 
 the recognition of expense associated with the fair value of the 119,050 shares of common stock paid in association with the arrangement 
 of the $25 million Keystone Equity Financing.                                                                                            |

| CC. | Reflects                                                                                    
 the $4.3 million gain on settlement of transaction expenses and deferred underwriting fees. |

| DD. | Reflects                                                                                 
 the amortization of the remaining debt discount related to the Convertible Bridge Notes. |

| EE. | Reflects                                                                                       
 the expensing of the $45.1 million of acquired Legacy CERo in-process research and development |

Note 5. Net Loss per Share Net loss per share was calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination and the related transactions, assuming the shares were outstanding since January 1, 2023. As the Business Combination and the related transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination and related have been outstanding for the entirety of the period presented. The following has been prepared to present the net loss per share, at the time of the Business Combination for the year ended December 31, 2023, both prior to and retroactively adjusted for the Reverse Stock Split:

|                                                         |     | Pre-Reverse 
 Stock Split |             |   |     | Post-Reverse 
 Stock Split  |             |   |
|:--------------------------------------------------------|:----|:------------|------------:|:--|:----|:-------------|------------:|:--|
| Pro forma net loss                                      |     | $           | (54,910,374 | ) |     | $            | (54,910,374 | )